Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kenneth P Johnson. (2012) Glatiramer acetate for treatment of relapsing–remitting multiple sclerosis. Expert Review of Neurotherapeutics 12:4, pages 371-384.
Read now
Read now
Articles from other publishers (27)
Harshad Devarbhavi, Herbert L. Bonkovsky, Mark Russo & Naga Chalasani. 2018. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
844
890.e17
.
J. Thöne, P. Rieckmann & R. Gold. 2015. Therapie-Handbuch Grundwerk inkl 6. Lfg.. Therapie-Handbuch Grundwerk inkl 6. Lfg.
1
12
.
Vera Weinstein, Rivka Schwartz, Iris Grossman, Benjamin Zeskind & J. Michael Nicholas. 2015. Non-Biological Complex Drugs. Non-Biological Complex Drugs
107
148
.
G Giovannoni, E Southam & E Waubant. (2012) Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Multiple Sclerosis Journal 18:7, pages 932-946.
Crossref
Crossref
Ewa Motta, Anna Gołba, Maciej Huć & Zofia Kazibutowska. (2012) Development of Guillain-Barré syndrome in a patient with multiple sclerosis during treatment with glatiramer acetate. Neurologia i Neurochirurgia Polska 46:2, pages 189-191.
Crossref
Crossref
Herbert L. Bonkovsky, Dean P. Jones, Mark W. Russo & Steven I. Shedlofsky. 2012. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
417
461
.
Huub Schellekens, Ety Klinger, Stefan Mühlebach, Jean-Francois Brin, Gert Storm & Daan J.A. Crommelin. (2011) The therapeutic equivalence of complex drugs. Regulatory Toxicology and Pharmacology 59:1, pages 176-183.
Crossref
Crossref
Robert Jay Schwartzman, Nicole Simpkins, Guillermo M. Alexander, Erin Reichenberger, Kristine Ward, Noah Lindenberg, David Topolsky & Pam Crilley. (2009) High-Dose Cyclophosphamide in the Treatment of Multiple Sclerosis. CNS Neuroscience & Therapeutics 15:2, pages 118-127.
Crossref
Crossref
Etienne C Hirsch & Stéphane Hunot. (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection?. The Lancet Neurology 8:4, pages 382-397.
Crossref
Crossref
D. L. Arnold, D. Campagnolo, H. Panitch, A. Bar-Or, J. Dunn, M. S. Freedman, S. K. Gazda & T. Vollmer. (2008) Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. Journal of Neurology 255:10, pages 1473-1478.
Crossref
Crossref
T VollmerH Panitch, A Bar-Or, J Dunn, MS Freedman, SK Gazda, D Campagnolo, F Deutsch & DL Arnold. (2008) Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Multiple Sclerosis Journal 14:5, pages 663-670.
Crossref
Crossref
Santhi Gorantla, Jianuo Liu, Tong Wang, Adelina Holguin, Hannah M. Sneller, Huanyu Dou, Jonathan Kipnis, Larisa Poluektova & Howard E. Gendelman. (2008) Modulation of innate immunity by copolymer-1 leads to neuroprotection in murine HIV-1 encephalitis. Glia 56:2, pages 223-232.
Crossref
Crossref
Lahar R. Mehta & Andrew D. Goodman. (2007) DISEASE-MODIFYING THERAPIES. CONTINUUM: Lifelong Learning in Neurology 13, pages 144-180.
Crossref
Crossref
Iris Grossman, Nili Avidan, Clara Singer, Dan Goldstaub, Liat Hayardeny, Eli Eyal, Edna Ben-Asher, Tamar Paperna, Itsik Pe'er, Doron Lancet, Jacques S. Beckmann & Ariel Miller. (2007) Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenetics and Genomics 17:8, pages 657-666.
Crossref
Crossref
Amjad Horani, Nidal Muhanna, Orit Pappo, Alaa Melhem, Carlos E. Alvarez, Sarit Doron, Wehbi Wehbi, Karussis Dimitrios, Scott L. Friedman & Rifaat Safadi. (2007) Beneficial effect of glatiramer acetate (Copaxone) on immune modulation of experimental hepatic fibrosis. American Journal of Physiology-Gastrointestinal and Liver Physiology 292:2, pages G628-G638.
Crossref
Crossref
Shih-Jen Tsai. (2007) Glatiramer acetate could be a potential therapeutic agent for Parkinson’s disease through its neuroprotective and anti-inflammatory effects. Medical Hypotheses 69:6, pages 1219-1221.
Crossref
Crossref
Shih-Jen Tsai. (2007) Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Medical Hypotheses 69:1, pages 145-148.
Crossref
Crossref
D. Teitelbaum, R. Arnon & M. Sela. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
173
185
.
Massimo Filippi, Jerry S Wolinsky & Giancarlo Comi. (2006) Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study. The Lancet Neurology 5:3, pages 213-220.
Crossref
Crossref
Michal Schwartz, Oleg Butovsky & Jonathan Kipnis. (2006) Does Inflammation in an Autoimmune Disease Differ from Inflammation in Neurodegenerative Diseases? Possible Implications for Therapy. Journal of Neuroimmune Pharmacology 1:1.
Crossref
Crossref
Herbert L. Bonkovsky, Dean P. Jones, Douglas R. LaBrecque & Steven I. Shedlofsky. 2006. Zakim and Boyer's Hepatology. Zakim and Boyer's Hepatology
503
550
.
Hans-Peter Hartung, Bernd C. Kieseier & Bernhard Hemmer. (2005) Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis. Journal of Neurology 252:S5, pages v30-v37.
Crossref
Crossref
Ana Patricia Perez Fiore & Yara Dadalti Fragoso. (2005) Tolerability, adverse events and compliance to glatiramer acetate in 28 patients with multiple sclerosis using the drug continuously for at least six months. Arquivos de Neuro-Psiquiatria 63:3b, pages 738-740.
Crossref
Crossref
Zsuzsa Keszthelyi. (2005) Glatiramer acetate and interferon beta-1a: a patient's view. The Lancet Neurology 4:6, pages 331.
Crossref
Crossref
ELENI SARLANI, EDWARD G. GRACE, BIRUTE A. BALCIUNAS & ANTHONY H. SCHWARTZ. (2005) Trigeminal neuralgia in a patient with multiple sclerosis and chronic inflammatory demyelinating polyneuropathy. The Journal of the American Dental Association 136:4, pages 469-476.
Crossref
Crossref
Naftali Kaminski & Anat Achiron. (2005) Can Blood Gene Expression Predict Which Patients with Multiple Sclerosis Will Respond to Interferon?. PLoS Medicine 2:2, pages e33.
Crossref
Crossref
Zografos Caramanos & Douglas L Arnold. (2005) Evidence for use of glatiramer acetate in multiple sclerosis. The Lancet Neurology 4:2, pages 74-75.
Crossref
Crossref